|
|
|||||||||||||||||||||||||||||||||||||||||
Allied World Assurance Company Holdings, AG Buyback
OLI recorded this information on 5/1/2014
Aspira Womens Health is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Co. markets and sells its products and related services, including: OVA1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; OVERA, a biomarker reflex intended to maintain OVA1's sensitivity while improving specificity; and Aspira Synergy, a decentralized testing platform and cloud service for decentralized global access of both protein biomarker and hereditary genetic testing.
Open the AWH Page at The Online Investor (in a new window) »
|
|